 NEW YORK, April 6, 2021 PRNewswire -- Hoth Therapeutics, Inc. NASDAQ: HOTH, a patient focused biopharmaceutical company, announced that it has engaged Worldwide Clinical Trials Worldwide, a full-service Contract Research Organization CRO for its upcoming Phase 2a dose ranging clinical trial of HT-001 for treatment of cutaneous toxicities associated with EGFR inhibitor therapy for cancer patients. Worldwide is a midsized, full-service, global CRO founded by physicians committed to advancing medical science. 